News

• 2024.10.21 news
  Notice of a special lecture on our PAI-1 inhibitor RS5614 at the 31st Japanese Society of Transfusion Medicine and Cell Therapy
• 2024.10.10 news
  Notice regarding head office relocation
• 2024.09.09 news
  Presentation of the pharmacological action of PAI-1 inhibitor RS5614 in non-small cell lung cancer at the 2024 World Conference on Lung Cancer (WCLC) in San Diego
• 2024.09.03 news
  Notice of publication of a newspaper article in Kahoku Shimpo regarding malignant melanoma treatment drug
• 2024.06.05 news
  Notice of Publication of Article on Immune Checkpoint Inhibitory Effect of PAI-1 Inhibitor RS5614
• 2024.01.19 news
  Notice of Publication of Article Related to the Development of RS5614, a PAI-1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer
• 2024.01.03 news
  Notice of Publication of Article on Results of Late Phase II Study of Novel Coronavirus Lung Injury
• 2023.11.13 news
  Notice of Publication of Article on Cutaneous Angiosarcoma Phase II Study Protocol
• 2023.09.29 news
  Notice of Publication of Article Related to the Development of RS5614, a PAI-1 Inhibitor, for the Treatment of Malignant Melanoma
• 2023.09.01 news
  Notice of Publication of Article on Our Pipeline in Global Bio Investment Magazine